GERN · NASDAQ · Biotechnology

Geron (GERN)

Markets RYTELO, the only approved telomerase inhibitor, for transfusion-dependent low-risk MDS patients.

$1.24
After hours0.00 (0.00%)
At close$1.24(−5.34%)